Understanding Rift Valley fever: Contributions of animal models to disease characterization and control

Molecular Immunology

Volumn 66, Issue 1, 2015, Pages 78-88

  Lorenzo, Gema ^a   López Gil, Elena ^a   Warimwe, George M ^b   Brun, Alejandro ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immune response; Non human primates; Pathogenesis; Rift Valley fever; Ruminants

Indexed keywords

ADENOVIRUS VACCINE; ANTIVIRUS AGENT; CHEMOKINE; CYTOKINE; DNA VACCINE; INTERFERON; RECOMBINANT INTERFERON; RIFT VALLEY FEVER VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BUNYAVIRIDAE; DRUG EFFICACY; EXPERIMENTAL INFECTION; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INNATE IMMUNITY; INOCULATION; NONHUMAN; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; REVIEW; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; RODENT; RUMINANT; SHEEP; VIRUS IMMUNITY; VIRUS REPLICATION; ANIMAL; DISEASE MODEL; HAPLORHINI; IMMUNOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HAPLORHINI; HUMANS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; RODENTIA; RUMINANTS;

EID: 84925534448     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.02.001     Document Type: Review

References (126)

1. Ahmad K. More deaths from Rift Valley fever in Saudi Arabia and Yemen. Lancet 2000, 356:1422.
2. Al-Hazmi M., Ayoola E.A., Abdurahman M., Banzal S., Ashraf J., El-Bushra A., Hazmi A., Abdullah M., Abbo H., Elamin A., Al-Sammani el T., Gadour M., Menon C., Hamza M., Rahim I., Hafez M., Jambavalikar M., Arishi H., Aqeel A. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin. Infect. Dis. 2003, 36:245-252.
3. Anderson G.W., Peters C.J. Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb. Pathog. 1988, 5:241-250.
4. Anderson G.W., Slone T.W., Peters C.J. Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb. Pathog. 1987, 2:283-293.
5. Anderson G.W., Slone T.W., Peters C.J. The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis. Arch. Virol. 1988, 102:187-196.
6. Andriamandimby S.F., Randrianarivo-Solofoniaina A.E., Jeanmaire E.M., Ravololomanana L., Razafimanantsoa L.T., Rakotojoelinandrasana T., Razainirina J., Hoffmann J., Ravalohery J.P., Rafisandratantsoa J.T., Rollin P.E., Reynes J.M. Rift Valley fever during rainy seasons, Madagascar, 2008 and 2009. Emerg. Infect. Dis. 2010, 16:963-970.
7. Antonis A.F., Kortekaas J., Kant J., Vloet R.P., Vogel-Brink A., Stockhofe N., Moormann R.J. Vertical transmission of Rift Valley fever virus without detectable maternal viremia. Vector Borne Zoonotic Dis. 2013, 13:601-606.
8. Anyamba A., Chretien J.P., Small J., Tucker C.J., Formenty P.B., Richardson J.H., Britch S.C., Schnabel D.C., Erickson R.L., Linthicum K.J. Prediction of a Rift Valley fever outbreak. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:955-959.
9. Anyamba A., Linthicum K.J., Small J., Britch S.C., Pak E., de La Rocque S., Formenty P., Hightower A.W., Breiman R.F., Chretien J.P., Tucker C.J., Schnabel D., Sang R., Haagsma K., Latham M., Lewandowski H.B., Magdi S.O., Mohamed M.A., Nguku P.M., Reynes J.M., Swanepoel R. Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006-2008 and possible vector control strategies. Am. J. Trop. Med. Hyg. 2010, 83:43-51.
10. Baer A., Austin D., Narayanan A., Popova T., Kainulainen M., Bailey C., Kashanchi F., Weber F., Kehn-Hall K. Induction of DNA damage signaling upon Rift Valley fever virus infection results in cell cycle arrest and increased viral replication. J. Biol. Chem. 2012, 287:7399-7410.
11. Barnard B.J. Rift Valley fever vaccine-antibody and immune response in cattle to a live and an inactivated vaccine. J. S. Afr. Vet. Assoc. 1979, 50:155-157.
12. Baskerville A., Hubbard K.A., Stephenson J.R. Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine. Res. Vet. Sci. 1992, 52:307-311.
13. Battles J.K., Dalrymple J.M. Genetic variation among geographic isolates of Rift Valley fever virus. Am. J. Trop. Med. Hyg. 1988, 39:617-631.
14. Benferhat R., Josse T., Albaud B., Gentien D., Mansuroglu Z., Marcato V., Soues S., Le Bonniec B., Bouloy M., Bonnefoy E. Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome. J. Virol. 2012, 86:11333-11344.
15. Besselaar T.G., Blackburn N.K. The effect of neutralizing monoclonal antibodies on early events in Rift Valley fever virus infectivity. Res. Virol. 1994, 145:13-19.
16. Bhardwaj N., Heise M.T., Ross T.M. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 2010, 4:e725.
17. Billecocq A., Spiegel M., Vialat P., Kohl A., Weber F., Bouloy M., Haller O. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 2004, 78:9798-9806.
18. Bird B.H., Maartens L.H., Campbell S., Erasmus B.J., Erickson B.R., Dodd K.A., Spiropoulou C.F., Cannon D., Drew C.P., Knust B., McElroy A.K., Khristova M.L., Albarino C.G., Nichol S.T. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 2011, 85:12901-12909.
19. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., Salman D., Saad M., Earhart K. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol. 2006, 78:787-791.
20. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., Haller O. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J. Virol. 2001, 75:1371-1377.
21. Brennan B., Welch S.R., McLees A., Elliott R.M. Creation of a recombinant Rift Valley fever virus with a two-segmented genome. J. Virol. 2011, 85:10310-10318.
22. Brown J.L., Dominik J.W., Morrissey R.L. Respiratory infectivity of a recently isolated Egyptian strain of Rift Valley fever virus. Infect. Immun. 1981, 33:848-853.
23. Busquets N., Lorenzo G., Lopez-Gil E., Rivas R., Solanes D., Galindo-Cardiel I., Abad F.X., Rodriguez F., Bensaid A., Warimwe G., Gilbert S.C., Domingo M., Brun A. Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs. Antiviral Res. 2014, 108:165-172.
24. Busquets N., Xavier F., Martin-Folgar R., Lorenzo G., Galindo-Cardiel I., del Val B.P., Rivas R., Iglesias J., Rodriguez F., Solanes D., Domingo M., Brun A. Experimental infection of young adult European breed sheep with Rift Valley fever virus field isolates. Vector Borne Zoonotic Dis. 2010, 10:689-696.
25. Caplen H., Peters C.J., Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 1985, 66(Pt 10):2271-2277.
26. Capstick P.B., Gosden D. Neutralizing antibody response of sheep to pantropic and neutrotropic Rift Valley fever virus. Nature 1962, 195:583-584.
27. Coackley W., Pini A., Gosden D. Experimental infection of cattle with pantropic Rift Valley fever virus. Res. Vet. Sci. 1967, 8:399-405.
28. Coackley W., Pini A., Gosden D. The immunity induced in cattle and sheep by inoculation of neurotropic or pantropic Rift Valley fever viruses. Res. Vet. Sci. 1967, 8:406-414.
29. Coetzer J.A., Ishak K.G. Sequential development of the liver lesions in new-born lambs infected with Rift Valley fever virus. I. Macroscopic and microscopic pathology. Onderstepoort. J. Vet. Res. 1982, 49:103-108.
30. Copeland A.M., Altamura L.A., Van Deusen N.M., Schmaljohn C.S. Nuclear relocalization of polyadenylate binding protein during Rift Valley fever virus infection involves expression of the NSs gene. J. Virol. 2013, 87:11659-11669.
31. Cosgriff T.M., Morrill J.C., Jennings G.B., Hodgson L.A., Slayter M.V., Gibbs P.H., Peters C.J. Hemostatic derangement produced by Rift Valley fever virus in rhesus monkeys. Rev. Infect. Dis. 1989, 11(Suppl. 4):S807-S814.
32. Daubney R., Hudson J., Garnham P.C. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa. J. Pathol. Bacteriol. 1931, 34:545-557.
33. Davies F.G., Linthicum K.J., James A.D. Rainfall and epizootic Rift Valley fever. Bull. World Health Organ. 1985, 63:941-943.
34. Di Nardo A., Rossi D., Saleh S.M., Lejlifa S.M., Hamdi S.J., Di Gennaro A., Savini G., Thrusfield M.V. Evidence of Rift Valley fever seroprevalence in the Saharawi semi-nomadic pastoralist system, Western Sahara. BMC Vet. Res. 2014, 10:92.
35. Dodd K.A., McElroy A.K., Jones M.E., Nichol S.T., Spiropoulou C.F. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. J. Virol. 2013, 87:6161-6171.
36. Dodd K.A., McElroy A.K., Jones T.L., Zaki S.R., Nichol S.T., Spiropoulou C.F. Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model. PLoS Negl. Trop. Dis. 2014, 8:e2874.
37. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B.F., Bouloy M. Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep. Vaccine 2010, 28:4581-4587.
38. Easterday B.C. Rift valley fever. Adv. Vet. Sci. 1965, 10:65-127.
39. Easterday B.C., Mc G.M., Rooney J.R., Murphy L.C. The pathogenesis of Rift Valley fever in lambs. Am. J. Vet. Res. 1962, 23:470-479.
40. Edwards J.F., Higgs S., Beaty B.J. Mosquito feeding-induced enhancement of Cache Valley Virus (Bunyaviridae) infection in mice. J. Med. Entomol. 1998, 35:261-265.
41. El-Harrak M., Martin-Folgar R., Llorente F., Fernandez-Pacheco P., Brun A., Figuerola J., Jimenez-Clavero M.A. Rift Valley and West Nile virus antibodies in camels, North Africa. Emerg. Infect. Dis. 2011, 17:2372-2374.
42. Engdahl C., Naslund J., Lindgren L., Ahlm C., Bucht G. The Rift Valley Fever virus protein NSm and putative cellular protein interactions. Virol. J. 2012, 9:139.
43. Francis T., Magill T.P. Rift Valley Fever: a report of three cases of laboratory infection and the experimental transmission of the disease to ferrets. J. Exp. Med. 1935, 62:433-448.
44. Galindo-Cardiel I., Busquets N., Velarde R., Abad F.X., Solanes D., Rivas R., Valle R., Brun A., Domingo M. Lymphoplasmacytic endotheliitis and anterior uveitis in sheep infected experimentally with Rift Valley fever virus. J. Comp. Pathol. 2012, 146:40-43.
45. Gommet C., Billecocq A., Jouvion G., Hasan M., Zaverucha do Valle T., Guillemot L., Blanchet C., van Rooijen N., Montagutelli X., Bouloy M., Panthier J.J. Tissue tropism and target cells of NSs-deleted Rift Valley fever virus in live immunodeficient mice. PLoS Negl. Trop. Dis. 2011, 5:e1421.
46. Gray K.K., Worthy M.N., Juelich T.L., Agar S.L., Poussard A., Ragland D., Freiberg A.N., Holbrook M.R. Chemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouse. PLoS Negl. Trop. Dis. 2012, 6:e1529.
47. Habjan M., Pichlmair A., Elliott R.M., Overby A.K., Glatter T., Gstaiger M., Superti-Furga G., Unger H., Weber F. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J. Virol. 2009, 83:4365-4375.
48. Harrington D.G., Lupton H.W., Crabbs C.L., Peters C.J., Reynolds J.A., Slone T.W. Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am. J. Vet. Res. 1980, 41:1559-1564.
49. Hartman A.L., Powell D.S., Bethel L.M., Caroline A.L., Schmid R.J., Oury T., Reed D.S. Aerosolized Rift Valley fever virus causes fatal encephalitis in african green monkeys and common marmosets. J. Virol. 2014, 88:2235-2245.
50. Hassan O.A., Ahlm C., Sang R., Evander M. The 2007 Rift Valley fever outbreak in Sudan. PLoS Negl. Trop. Dis. 2011, 5:e1229.
51. Hofmann H., Li X., Zhang X., Liu W., Kuhl A., Kaup F., Soldan S.S., Gonzalez-Scarano F., Weber F., He Y., Pohlmann S. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J. Virol. 2013, 87:4384-4394.
52. Hunter P., Erasmus B.J., Vorster J.H. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort. J. Vet. Res. 2002, 69:95-98.
53. Ikegami T., Makino S. Rift valley fever vaccines. Vaccine 2009, 27(Suppl. 4):D69-D72.
54. Ikegami T., Makino S. The pathogenesis of Rift Valley fever. Viruses 2011, 3:493-519.
55. Ikegami T., Narayanan K., Won S., Kamitani W., Peters C.J., Makino S. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog. 2009, 5:e1000287.
56. Ikegami T., Peters C.J., Makino S. Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system. J. Virol. 2005, 79:5606-5615.
57. Ikegami T., Won S., Peters C.J., Makino S. Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment. J. Virol. 2005, 79:12106-12111.
58. Indran S.V., Ikegami T. Novel approaches to develop Rift Valley fever vaccines. Front Cell. Infect. Microbiol. 2012, 2:131.
59. Jansen van Vuren P., Tiemessen C.T., Paweska J.T. Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS ONE 2011, 6:e25027.
60. Kading R.C., Crabtree M.B., Bird B.H., Nichol S.T., Erickson B.R., Horiuchi K., Biggerstaff B.J., Miller B.R. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis. 2014, 8:e2670.
61. Kainulainen M., Habjan M., Hubel P., Busch L., Lau S., Colinge J., Superti-Furga G., Pichlmair A., Weber F. Virulence factor NSs of Rift Valley fever virus recruits the F-box protein FBXO3 to degrade subunit p62 of general transcription factor TFIIH. J. Virol. 2014, 88:3464-3473.
62. Kalveram B., Lihoradova O., Ikegami T. NSs protein of Rift Valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62. J. Virol. 2011, 85:6234-6243.
63. Kalveram B., Lihoradova O., Indran S.V., Lokugamage N., Head J.A., Ikegami T. Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR. Virology 2013, 435:415-424.
64. Kortekaas J. One Health approach to Rift Valley fever vaccine development. Antiviral Res. 2014, 106:24-32.
65. Kortekaas J., Antonis A.F., Kant J., Vloet R.P., Vogel A., Oreshkova N., de Boer S.M., Bosch B.J., Moormann R.J. Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 2012, 30:3423-3429.
66. Kortekaas J., Zingeser J., de Leeuw P., de La Rocque S., Unger H., Moormann R.J. Rift Valley fever vaccine development, progress and constraints. Emerg. Infect. Dis. 2011, 17:e1.
67. Le Coupanec A., Babin D., Fiette L., Jouvion G., Ave P., Misse D., Bouloy M., Choumet V. Aedes mosquito saliva modulates Rift Valley fever virus pathogenicity. PLoS Negl. Trop. Dis. 2013, 7:e2237.
68. Le May N., Dubaele S., Proietti De Santis L., Billecocq A., Bouloy M., Egly J.M. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 2004, 116:541-550.
69. Le May N., Mansuroglu Z., Leger P., Josse T., Blot G., Billecocq A., Flick R., Jacob Y., Bonnefoy E., Bouloy M. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 2008, 4:e13.
70. Logan T.M., Linthicum K.J., Davies F.G., Binepal Y.S., Roberts C.R. Isolation of Rift Valley fever virus from mosquitoes (Diptera: Culicidae) collected during an outbreak in domestic animals in Kenya. J. Med. Entomol. 1991, 28:293-295.
71. Lopez-Gil E., Lorenzo G., Hevia E., Borrego B., Eiden M., Groschup M., Gilbert S.C., Brun A. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl. Trop. Dis. 2013, 7:e2309.
72. Lorenzo G., Martin-Folgar R., Hevia E., Boshra H., Brun A. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine 2010, 28:2937-2944.
73. Lorenzo G., Martin-Folgar R., Rodriguez F., Brun A. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 2008, 26:5255-5262.
74. Lozach P.Y., Kuhbacher A., Meier R., Mancini R., Bitto D., Bouloy M., Helenius A. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe. 2011, 10:75-88.
75. Mansuroglu Z., Josse T., Gilleron J., Billecocq A., Leger P., Bouloy M., Bonnefoy E. Nonstructural NSs protein of Rift Valley fever virus interacts with pericentromeric DNA sequences of the host cell, inducing chromosome cohesion and segregation defects. J. Virol. 2010, 84:928-939.
76. McElroy A.K., Nichol S.T. Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 2012, 422:6-12.
77. McIntosh B.M., Dickinson D.B., dos Santos I. Rift Valley fever. 3. Viraemia in cattle and sheep. 4. The susceptibility of mice and hamsters in relation to transmission of virus by mosquitoes. J. S. Afr. Vet. Assoc. 1973, 44:167-169.
78. Montgomery R.E. Report of the Veterinary Department for the Year 1912-1913 1913, Ann. Rep. Dept. Agric., Nairobi, Kenya.
79. Morrill J.C., Carpenter L., Taylor D., Ramsburg H.H., Quance J., Peters C. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 1991, 9:35-41.
80. Morrill J.C., Czarniecki C.W., Peters C. Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey. J. Interferon. Res. 1991, 11:297-304.
81. Morrill J.C., Jennings G.B., Cosgriff T.M., Gibbs P.H., Peters C.J. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev. Infect. Dis. 1989, 11(Suppl. 4):S815-S825.
82. Morrill J.C., Jennings G.B., Johnson A.J., Cosgriff T.M., Gibbs P.H., Peters C.J. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch. Virol. 1990, 110:195-212.
83. Morrill J.C., Laughlin R.C., Lokugamage N., Pugh R., Sbrana E., Weise W.J., Adams L.G., Makino S., Peters C.J. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 2013, 31:559-565.
84. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am. J. Vet. Res. 1997, 58:1104-1109.
85. Morrill J.C., Peters C.J. Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 2003, 21:2994-3002.
86. Morrill J.C., Peters C. Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine. J. Infect. Dis. 2011, 204:617-625.
87. Morrill J.C., Peters C. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent Rift Valley fever virus. J. Infect. Dis. 2011, 204:229-236.
88. Muller R., Saluzzo J.F., Lopez N., Dreier T., Turell M., Smith J., Bouloy M. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 1995, 53:405-411.
89. Nfon C.K., Marszal P., Zhang S., Weingartl H.M. Innate immune response to Rift Valley fever virus in goats. PLoS. Negl. Trop. Dis. 2012, 6:e1623.
90. Nichol S.T., Beaty B.J., Elliott R.M., Goldbach R.W., Plyusnin A., Tesh R.B. The Bunyaviridae. Virus Taxonomy. Classification and Nomenclature of viruses. 8th Report of the ICTV 2005, 695-716. Elsevier Academic Press, London. C. Fauquet, M.A. Mayo, L.S.M. Maniloff, U. Desselberger, L.A. Ball (Eds.).
91. Olaleye O.D., Tomori O., Fajimi J.L., Schmitz H. Experimental infection of three Nigerian breeds of sheep with the Zinga strain of the Rift Valley Fever virus. Rev. Elev. Med. Vet. Pays. Trop. 1996, 49:6-16.
92. Oreshkova N., Cornelissen L.A., de Haan C.A., Moormann R.J., Kortekaas J. Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen. Vaccine 2014, 32:5323-5329.
93. Oreshkova N., van Keulen L., Kant J., Moormann R.J., Kortekaas J. A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs. PLoS ONE 2013, 8:e77461.
94. Peters C.J., Jones D., Trotter R., Donaldson J., White J., Stephen E., Slone T.W. Experimental Rift Valley fever in rhesus macaques. Arch. Virol. 1988, 99:31-44.
95. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., Stephen E.L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 1986, 6:285-297.
96. Pittman P.R., Liu C.T., Cannon T.L., Makuch R.S., Mangiafico J.A., Gibbs P.H., Peters C.J. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999, 18:181-189.
97. Randall R., Binn L.N., Harrison V.R. Immunization against Rift Valley fever virus studies on the immunogenicity of lyophilized formalin-inactivated vaccine. J. Immunol. 1964, 93:293-299.
98. Randall R., Gibbs C.J., Aulisio C.G., Binn L.N., Harrison V.R. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. J. Immunol. 1962, 89:660-671.
99. Reagan K.L., Machain-Williams C., Wang T., Blair C.D. Immunization of mice with recombinant mosquito salivary protein D7 enhances mortality from subsequent West Nile virus infection via mosquito bite. PLoS Negl. Trop. Dis. 2012, 6:e1935.
100. Reed C., Lin K., Wilhelmsen C., Friedrich B., Nalca A., Keeney A., Donnelly G., Shamblin J., Hensley L.E., Olinger G., Smith D.R. Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. PLoS Negl. Trop. Dis. 2013, 7:e2156.
101. Reed C., Steele K.E., Honko A., Shamblin J., Hensley L.E., Smith D.R. Ultrastructural study of Rift Valley fever virus in the mouse model. Virology 2012, 431:58-70.
102. Ritter M., Bouloy M., Vialat P., Janzen C., Haller O., Frese M. Resistance to Rift Valley fever virus in Rattus norvegicus: genetic variability within certain 'inbred' strains. J. Gen. Virol. 2000, 81:2683-2688.
103. Roger M., Girard S., Faharoudine A., Halifa M., Bouloy M., Cetre-Sossah C., Cardinale E. Rift valley fever in ruminants, Republic of Comoros, 2009. Emerg. Infect. Dis. 2011, 17:1319-1320.
104. Ross T.M., Bhardwaj N., Bissel S.J., Hartman A.L., Smith D.R. Animal models of Rift Valley fever virus infection. Virus Res. 2012, 163:417-423.
105. Shieh W.J., Paddock C.D., Lederman E., Rao C.Y., Gould L.H., Mohamed M., Mosha F., Mghamba J., Bloland P., Njenga M.K., Mutonga D., Samuel A.A., Guarner J., Breiman R.F., Zaki S.R. Pathologic studies on suspect animal and human cases of Rift Valley fever from an outbreak in Eastern Africa, 2006-2007. Am. J. Trop. Med. Hyg. 2012, 83:38-42.
106. Sissoko D., Giry C., Gabrie P., Tarantola A., Pettinelli F., Collet L., D'Ortenzio E., Renault P., Pierre V. Rift Valley fever, Mayotte, 2007-2008. Emerg. Infect. Dis. 2009, 15:568-570.
107. Smith D.R., Bird B.H., Lewis B., Johnston S.C., McCarthy S., Keeney A., Botto M., Donnelly G., Shamblin J., Albarino C.G., Nichol S.T., Hensley L.E. Development of a novel nonhuman primate model for Rift Valley fever. J. Virol. 2012, 86:2109-2120.
108. Smith D.R., Steele K.E., Shamblin J., Honko A., Johnson J., Reed C., Kennedy M., Chapman J.L., Hensley L.E. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 2010, 407:256-267.
109. Soi R.K., Rurangirwa F.R., McGuire T.C., Rwambo P.M., DeMartini J.C., Crawford T.B. Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clin. Vaccine Immunol. 2010, 17:1842-1849.
110. Sow A., Faye O., Ba Y., Ba H., Diallo D., Loucoubar C., Boushab M., Barry Y., Diallo M., Sall A.A. Rift Valley fever outbreak, southern Mauritania, 2012. Emerg. Infect. Dis. 2014, 20:296-299.
111. Spik K., Shurtleff A., McElroy A.K., Guttieri M.C., Hooper J.W., SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006, 24:4657-4666.
112. Styer L.M., Lim P.Y., Louie K.L., Albright R.G., Kramer L.D., Bernard K.A. Mosquito saliva causes enhancement of West Nile virus infection in mice. J. Virol. 2011, 85:1517-1527.
113. Swanepoel R., Struthers J.K., Erasmus M.J., Shepherd S.P., McGillivray G.M., Shepherd A.J., Hummitzsch D.E., Erasmus B.J., Barnard B.J. Comparative pathogenicity and antigenic cross-reactivity of Rift Valley fever and other African phleboviruses in sheep. J. Hyg. (Lond.) 1986, 97:331-346.
114. Terasaki K., Won S., Makino S. The C-terminal region of Rift Valley fever virus NSm protein targets the protein to the mitochondrial outer membrane and exerts antiapoptotic function. J. Virol. 2013, 87:676-682.
115. Tomori O. Clinical, virological and serological response of the West African dwarf sheep to experimental infection with different strains of Rift Valley fever virus. Res. Vet. Sci. 1979, 26:152-159.
116. Van der Lugt J.J., Coetzer J.A., Smit M.M. Distribution of viral antigen in tissues of new-born lambs infected with Rift Valley fever virus. Onderstepoort. J. Vet. Res. 1996, 63:341-347.
117. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006, 24:7181-7189.
118. Warimwe G.M., Lorenzo G., Lopez-Gil E., Reyes-Sandoval A., Cottingham M.G., Spencer A.J., Collins K.A., Dicks M.D., Milicic A., Lall A., Furze J., Turner A.V., Hill A.V., Brun A., Gilbert S.C. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol. J. 2013, 10:349.
119. Weingartl H.M., Miller M., Nfon C., Wilson W. Development of a Rift Valley fever virus viremia challenge model in sheep and goats. Vaccine 2014, 32:2337-2344.
120. Weingartl H.M., Nfon C.K., Zhang S., Marszal P., Wilson W.C., Morrill J.C., Bettinger G.E., Peters C. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep. Vaccine 2014, 32:2345-2349.
121. Weingartl H.M., Zhang S., Marszal P., McGreevy A., Burton L., Wilson W. Rift Valley fever virus incorporates the 78kDa glycoprotein into virions matured in mosquito C6/36 cells. PLoS ONE 2014, 9:e87385.
122. Wichgers Schreur P.J., Oreshkova N., Moormann R.J., Kortekaas J. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. J. Virol. 2014, 88:10883-10893.
123. Won S., Ikegami T., Peters C.J., Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 2007, 81:13335-13345.
124. Xu W., Watts D.M., Costanzo M.C., Tang X., Venegas L.A., Jiao F., Sette A., Sidney J., Sewell A.K., Wooldridge L., Makino S., Morrill J.C., Peters C.J., Kan-Mitchell J. The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PLoS ONE 2013, 8:e59210.
125. Yedloutschnig R.J., Dardiri A.H., Mebus C.A., Walker J.S. Abortion in vaccinated sheep and cattle after challenge with Rift Valley fever virus. Vet. Rec. 1981, 109:383-384.
126. Yedloutschnig R.J., Dardiri A.H., Walker J.S., Peters C.J., Eddy G.A. Immune response of steers, goats and sheep to inactivated Rift Valley Fever vaccine. Proc. Annu. Meet. U.S. Anim. Health Assoc. 1979, 253-260.